SNUD Committee Meeting
Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
MINUTES OF PROCEEDINGS
Meeting No. 52
Tuesday, August 27, 2002
The Special Committee on Non-Medical Use of Drugs met in a televised session at 9:40 a.m. this day, in Room 237-C, Centre Block, the Chair, Paddy Torsney, presiding.
Members of the Committee present: Carole-Marie Allard, Bernard Bigras, Derek Lee, Kevin Sorenson, Paddy Torsney, Randy White.
In attendance: From the Library of Parliament: Chantal Collin and Marilyn Pilon, Research Officers
Witnesses: From the Canadian Pharmacists Association: Dr. Barry Power, PharmD, Director of Practice Development; Shelley Stepanuik, Vice President. From the National Association of Pharmacy Regulatory Authorities: Jeff May, Past President; Barbara Wells, Executive Director. From Purdue Pharma: Andrew Darke, PhD, Vice-President, Scientific Affairs; Kathryn Raymond, Manager, Health and Education; Dr. Roman Jovey, M.D.
Pursuant to the Order of Reference adopted by the House of Commons on Thursday, May 17, 2001, consideration of the factors underlying or relating to the non-medical use of drugs, and of Wednesday, April 17, 2002, referring the subject matter of Bill C-344, An Act to amend the Contraventions Act and the Controlled Drugs and Substances Act (marihuana) to the Special Committee.
The witnesses from the National Association of Pharmacy Regulatory Authorities and the Canadian Pharmacists Association made statements and answered questions.
At 11:07 a.m. the sitting was suspended.
At 11:15 a.m. the sitting resumed.
The witnesses from Purdue Pharma made statements and answered questions.
At 12:45 p.m., the Committee adjourned to the call of the Chair.
Carol Chafe
Clerk of the Committee